Pulse Biosciences, Inc. (6L8)
Munich
Closed
Aug 24, 2026
Day's Range
42.6052 wk Range
11.10Overview - 6L8 - Pulse Biosciences, Inc.
Key Statistics
Valuation
Enterprise Value
-73.20M
P/E (Trailing)
‪-39.44‬
PEG Ratio
‪-1.38‬
Price / Book
‪29.62‬
EV / EBITDA
‪0.96‬
Profitability
Gross Margin
‪37.09%‬
Profit Margin
‪-54.00%‬
Operating Margin
‪-21,982.57%‬
Return on Assets
‪-76.98%‬
Return on Equity
‪-90.23%‬
Ownership
Shares Outstanding
69.20M
Price stats
50-Day Avg
‪28.26‬
200-Day Avg
‪19.25‬
Peers - 6L8 - Pulse Biosciences, Inc.
Peer Comparison
Compared with companies in Medical Instruments & Supplies listed on Munich.
- 6L8MunichPulse Biosciences, Inc.+50.39%52-week change-23.70P/E (Trailing)‪-54.00%‬Profit Margin
- UG2MunichAngiodynamics Inc.+41.18%52-week change-15.45P/E (Trailing)‪54.62%‬Profit Margin
- 1MDMunichModern Dental Group Ltd.+35.39%52-week change1.40P/E (Trailing)‪55.79%‬Profit Margin
- 6XTMunichAsahi Intecc Co., Ltd.+34.86%52-week change—P/E (Trailing)‪67.68%‬Profit Margin
- WPSMunichWest Pharmaceutical Services, Inc.+30.49%52-week change44.15P/E (Trailing)‪35.91%‬Profit Margin
- EP3MunichOrasure Technologies Inc.+23.03%52-week change—P/E (Trailing)—Profit Margin
- S5U5MunichSafilo Group S.p.A.+20.91%52-week change16.15P/E (Trailing)‪60.94%‬Profit Margin
Profile Summary - 6L8 - Pulse Biosciences, Inc.
About
Pulse Biosciences, Inc. is a bioelectric medicine company specializing in the development of novel Nanosecond Pulsed Field Ablation (nsPFA) platforms. Its primary focus centers on the patented nPulse technology, which enables precise, non-thermal ablation of soft tissues for applications in dermatology, cardiology,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
